Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1700 - Erbitux conjugated zinc oxide nanoparticles to enhance antitumor efficiency via targeted drug delivery system for breast cancer therapy (141P)


18 Nov 2017


Poster lunch


Cytotoxic Therapy;  Clinical Research;  Breast Cancer


Karuppaiya Vimala


Annals of Oncology (2017) 28 (suppl_10): x39-x41. 10.1093/annonc/mdx658


K. Vimala, K. Soundarapandian

Author affiliations

  • Zoology, Periyar University, 636011 - Salem/IN


Abstract 1700


Owing to the presence of multidrug resistance in tumor cells, conventional chemotherapy remains clinically intractable. To enhance the therapeutic efficacy of chemotherapeutic agents, targeting strategies based on polyethylene glycol coated zinc oxide nanoparticles modified with targeting ligands have gained significant attention in cancer therapy


We used the green‐bio method to synthesize folic acid modified erbitux conjugated zinc oxide nanoparticles complex for its use as a cancer‐targeted drug delivery system to achieve enhanced cellular uptake and anticancer efficacy. To investigate the expression level of E2F3 protein RT‐PCR and western blotting analysis was carried out.


In the present investigation, we synthesized folic acid (FA)-modified polyethylene glycol coated zinc oxide nanoparticles (PEG-ZnO NPs) loaded with erbitux (ErB) using a bio organic method, followed by FA adsorption on the surface of NPs. The FA-modified PEG-ZnO NPs were characterized in terms of particle morphology and size, encapsulation efficiency and drug release. Furthermore, the cytotoxicity and cellular uptake of the drug-loaded PEG-ZnO NPs were evaluated in breast cancer cells in vitro. We found that FA-modified ErB-PEG-ZnO NPs showed the highest cytotoxicity effect and cellular uptake efficiency under folic acid receptor mediation in breast cancer cells compared with unmodified PEG-ZnO NPs and free drug. The cellular uptake efficiency of FA-modified PEG-ZnO NPs appeared to be facilitated by the applied PEG-ZnO NPs field, but the difference did not reach statistical significance.


This study illustrates that this proposed formulation can be used as one new alternative treatment for patients bearing inaccessible tumors. Thus, functionalized-ZnO NPs could be used as a novel nanomaterial for selective chemotherapy.

Clinical trial indentification


Clinical trial identification


Legal entity responsible for the study

Periyar University, Department of Zoology, Division of Cancer Nanomedicine




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.